Nuvation Bio's stock price has jumped by 12% on the London Stock Exchange, following the announcement of plans to expand its safusidenib clinical trial. The company's shares were trading at 145.50p as of 10:30 BST, a significant increase from their opening price of 130.10p. The expansion of the safusidenib trial is a major development for Nuvation Bio, as it looks to bring its treatment for a rare blood disorder to more patients.
Nuvation Bio Stock Jumps 12% on Plans to Expand Safusidenib Trial
UKPulse Markets DeskNuvation Bio's stock price has surged 12% following the announcement of plans to expand its safusidenib clinical trial. The trial aims to treat patients with a rare blood disorder.
- Nuvation Bio's stock price has risen 12% following the announcement of expanded safusidenib clinical trial plans.
- The safusidenib trial targets a rare blood disorder affecting patients.
- The expansion plans have been welcomed by investors as a potential catalyst for future growth.
Why this matters: The success of Nuvation Bio's safusidenib trial has significant implications for patients with rare blood disorders in the UK, who may have limited access to effective treatments.
What this means for you: What this means for you: While the expanded safusidenib trial is a positive development for patients with rare blood disorders, it is unclear how long it will take for the treatment to become available in the UK.